Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
Data Policies
EDITORIAL
Pirfenidone in idiopathic pulmonary fibrosis
| 1 | 2nd Pneumonology Department, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece |
| 2 | 1st Pneumonology Department, “Sotiria” Chest Diseases Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece |
| 3 | 7th Pneumonology Department, “Sotiria” Chest Diseases Hospital, Athens, Greece |
| 4 | 6th Pneumonology Department, “Sotiria” Chest Diseases Hospital, Athens, Greece |
CORRESPONDING AUTHOR
Spyros A Papiris
2nd Pneumonology Dept “Attikon” University Hospital, 1 Rimini Street 12462, Haidari, Greece
2nd Pneumonology Dept “Attikon” University Hospital, 1 Rimini Street 12462, Haidari, Greece
Pneumon 2012;25(2):145–147
KEYWORDS
REFERENCES (22)
1.
Raghu G, Harold R, Collard HR, et al. An Official ATS/ERS/JRS/ ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 2011; 183:788-824.
3.
Bouros D, Tzouvelekis A. Interferon-gamma for the treatment of idiopathic pulmonary fibrosis. Pneumon 2009; 22:13-17.
4.
Papiris SA, Manali ED, Kolilekas L, et al. Idiopathic Pulmonary Fibrosis Acute Exacerbations: Unravelling Ariadne’s thread. Crit Care 2010; 14:246.
5.
Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010; 3:16.
6.
Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159:1061-1069.
7.
Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002; 41:1118-1123.
8.
Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040–1047.
9.
Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821–829.
10.
Swigris J, Fairclough D. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36:695–696; author reply 696–698.
11.
Collard HR. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J 2010; 35:728-729.
12.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760–1769.
13.
Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011 21; 377:1727-1729.
14.
Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531-537.
15.
Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:830–836.
16.
du Bois RM, Weycker D, Albera C, et al. Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2011; 184:1382-1389.
17.
Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77:371–383.
18.
Man-Son-Hing M, Laupacis A, O’Rourke K, et al. Determination of the clinical importance of study results. J Gen Intern Med 2002; 17: 469–476.
19.
D’Agostino RB. Changing End Points in Breast-Cancer Drug Approval — The Avastin Story. N Engl J Med 2011; 365:e2.
20.
McKee AE, Farrell AT, Pazdur R, Woodcock J. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist 2010; 15:Suppl 1:13-18.
21.
Food and Drug Administration Oncologic Drug Advisory Committee. Transcript of the July 20, 2010, meeting. (http://www.fda.gov/downloads/A....).
22.
Papiris S, Kagouridis K, Kolilekas K, Triantafillidou C, TsangarisI, ManaliE. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation? Eur Respir J 2012; 39: in press.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.